Pain Therapeutics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

You can watch PTIE and buy or sell other stocks, ETFs, and their options commission-free!

About PTIE

Cassava Sciences, Inc. engages in the development of novel drugs and diagnostics. It focuses on developing product candidates intended for the treatment of Alzheimer’s disease, including PTI-125 and PTI-125Dx. 

CEO
Richard Jon Barry
CEORichard Jon Barry
Employees
Employees
Headquarters
Austin, Texas
HeadquartersAustin, Texas
Founded
1998
Founded1998
Employees
Employees

PTIE Key Statistics

Market cap
100.96M
Market cap100.96M
Price-Earnings ratio
-0.95
Price-Earnings ratio-0.95
Dividend yield
Dividend yield
Average volume
766.95K
Average volume766.95K
High today
High today
Low today
Low today
Open price
Open price
Volume
0.00
Volume0.00
52 Week high
$4.98
52 Week high$4.98
52 Week low
$1.15
52 Week low$1.15

Stock Snapshot

With a market cap of 100.96M, Pain Therapeutics(PTIE) trades at $6.01. The stock has a price-to-earnings ratio of -0.95.

On 2026-03-11, Pain Therapeutics(PTIE) stock opened at —, reached a high of —, and a low of —.

The Pain Therapeutics(PTIE)'s current trading volume is 0, compared to an average daily volume of 766.95K.

During the past year, Pain Therapeutics(PTIE) stock moved between $1.15 at its lowest and $4.98 at its peak.

During the past year, Pain Therapeutics(PTIE) stock moved between $1.15 at its lowest and $4.98 at its peak.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.